Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study

Bulut, Esra; Alak, Zehra; Dokuzlar, Ozge; Kocyigit, Suleyman; SOYSAL, PINAR; Smith, Lee; IŞIK, AHMET

doi:10.1016/j.archger.2020.104013

Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study

Bulut E. A., Alak Z. Y. S., Dokuzlar O., Kocyigit S. E., SOYSAL P., Smith L., ...Daha Fazla

ARCHIVES OF GERONTOLOGY AND GERIATRICS, cilt.88, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 88
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.archger.2020.104013
Dergi Adı: ARCHIVES OF GERONTOLOGY AND GERIATRICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, ASSIA, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
Anahtar Kelimeler: DPP-4 inhibitors, Cognitive decline, Metabolic outcome, Diabetes mellitus, Alzheimer's disease, Older adults
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM.